<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02112656</url>
  </required_header>
  <id_info>
    <org_study_id>104-13-302</org_study_id>
    <nct_id>NCT02112656</nct_id>
  </id_info>
  <brief_title>Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)</brief_title>
  <acronym>OPTIMA</acronym>
  <official_title>A Phase III, Randomized, Double Blind, Dummy-Controlled Study of ThermoDox® (Lyso-Thermosensitive Liposomal Doxorubicin-LTLD) in Hepatocellular Carcinoma (HCC) Using Standardized Radiofrequency Ablation (RFA) Treatment Time ≥ 45 Minutes for Solitary Lesions ≥ 3 cm to ≤ 7 cm</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celsion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celsion</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether ThermoDox, a thermally sensitive liposomal
      doxorubicin, is effective in the treatment of non-resectable hepatocellular carcinoma when
      used in conjunction with standardized radiofrequency ablation (sRFA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase III, randomized, double blind, dummy controlled safety and efficacy study of
      ThermoDox plus sRFA compared to sRFA plus dummy infusion using standardized treatment dwell
      time for solitary HCC lesions ≥ 3.0 cm to ≤ 7.0 cm. An sRFA treatment for this protocol is
      defined as the dwell time of ≥ 45 minutes measured from the first activation of the RFA probe
      through removal of the RFA probe after the final ablation cycle or deployment.

      The 50 mg/m2 ThermoDox or dummy infusion will be administered IV over 30 minutes. As part of
      blinded pre-medication ThermoDox treated subjects will receive 20 mg of dexamethasone orally
      24 hours prior to the drug infusion for infusion reaction prophylaxis. Subjects on the
      control arm will receive a matching dummy pre-medication pill orally at 24 hours prior to
      infusion of the study treatment. Thirty minutes prior to receiving the ThermoDox infusion,
      subjects will receive a blinded dose of 20 mg of IV dexamethasone, 50 mg IV diphenhydramine
      and either 50 mg of IV ranitidine or 20 mg of IV famotidine. Subjects on the control arm will
      receive a masked dummy pre-medication pill orally at 24 hours prior to infusion of the study
      medication, and a dummy infusion 30 minutes prior to dummy infusion of Sodium Chloride 0.9%
      or 5% Dextrose (D5W). RFA will be initiated approximately at a minimum of 15 minutes after
      the initiation of study drug infusion and should be completed no later than 3 hours after
      study drug infusion initiation. The goal is to reach a &gt; 45 minute dwell time which can be
      achieved by employing at least four ablation cycles or deployments in order to ablate the
      tumor as well as a 360º 1.0 cm tumor-free margin surrounding the tumor.with an estimated
      overall procedure time of less than 3 hours.

      A subject who has an incomplete ablation is eligible for 1 retreatment procedure within 21
      days after the radiological imaging exam showing residual disease at Day 28. Subjects will be
      retreated only once with the same RFA equipment and treatment assigned at randomization.
      Subjects with a complete ablation after retreatment will be followed both for PFS and for OS.

      If after 2 ablations the subject has local, distant intrahepatic, or extrahepatic HCC, then
      the subject will be considered a treatment failure and will have met the PFS endpoint. The
      subject will be followed for OS every 3 months. Among subjects who are not treatment
      failures, five repeat treatments are permitted to treat a recurrent lesion or to treat
      newly-identified local or distant intrahepatic lesions at the Investigator's discretion after
      the PFS endpoint is reported and with agreement from the Sponsor. The subject must be
      eligible for retreatment consistent with the safety eligibility criteria and will be
      retreated with the same randomized treatment.

      CT or MRI imaging will be used to assess the effectiveness of the ablation therapy. The blind
      will be maintained at the level of the imaging reads. Investigator determined radiological
      progression must be observed and recorded prior to beginning alternate treatments for HCC.
      Posttreatment imaging will be obtained at months 1, 5, 9, 13, 17, 21, 25, then every 6 months
      (+/- 2 weeks) until radiological progression is seen. Adverse event assessments and
      laboratory examinations will occur at each visit. All subjects will be monitored throughout
      the investigational period.

      Patients that meet inclusion/exclusion criteria may be at risk for contrast-induced
      nephropathy (CIN) when undergoing the required CT with contrast procedures. The investigators
      must be mindful of the risk factors associated with CIN and employ strategies to reduce the
      risk of CIN. In subjects with diabetes or borderline renal function (creatinine greater than
      1.5 mg/dL) special precautions (e.g. hydration, contrast dose reduction, follow up creatinine
      determination) should be employed. An accepted procedure is adequate intravenous volume
      expansion with isotonic saline (1.0 - 1.5 mL/kg per hour) for 3-12 hours before the procedure
      and continued for 6-24 hours if clinically indicated and based on the treating physician's
      medical judgment.

      All randomized subjects will be followed for safety and overall survival.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>5 years</time_frame>
    <description>Overall survival is defined as the time (in months) from the date of randomization to the death date.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>5 years</time_frame>
    <description>Progression-free survival is defined as the time (in months) from the date of randomization until the date of the Investigator-assessed radiological disease progression or death due to any cause.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">550</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>ThermoDox 50 mg/m2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ThermoDox plus standardized RFA using standardized treatment dwell time for solitary HCC lesions ≥ 3.0 cm to ≤ 7.0 cm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dummy infusion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>standardized RFA alone using standardized treatment dwell time for solitary HCC lesions ≥ 3.0 cm to ≤ 7.0 cm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ThermoDox</intervention_name>
    <description>Thermally Sensitive Liposomal Doxorubicin 50 mg/m2 Single 30 minute intravenous infusion</description>
    <arm_group_label>ThermoDox 50 mg/m2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dummy infusion</intervention_name>
    <description>Sodium Chloride 0.9% or 5% Dextrose (D5W), Single 30 minute intravenous infusion</description>
    <arm_group_label>Dummy infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female ≥ 18 years of age.

          2. Diagnosed with a single HCC lesion ≥ 3.0 cm but ≤ 7.0 cm in maximum diameter based on
             diagnosis at screening.

               -  Subjects meeting the American Association for the Study of Liver Disease (AASLD)
                  criteria may be randomized without a biopsy, but will undergo a biopsy during the
                  RFA procedure unless contraindicated or unattainable.

               -  Subjects not meeting the AASLD criteria for HCC will need a biopsy to confirm HCC
                  prior to randomization.

          3. Be an appropriate candidate for receiving RFA as a medically indicated treatment as
             evaluated by the following factors:

               -  The position and accessibility of the target lesion allows for the safe
                  administration of multiple ablation cycles or deployments to achieve a probe
                  dwell time of ≥ 45 minutes.

               -  Not a candidate for surgical resection according to the local guidelines for
                  resection and in the Investigator's judgment.

          4. Child-Pugh Class A without either current encephalopathy or ascites.

          5. Left Ventricular Ejection Fraction (LVEF) ≥ 50%.

          6. Eastern Cooperative Oncology Group (ECOG) performance status 0.

          7. Willing to sign an informed consent form, indicating awareness of the investigational
             nature of this study that is in keeping with the policies of the institution.

        Exclusion Criteria:

          1. Is scheduled for liver transplantation

          2. Expected ablation volume &gt; 30% of total liver volume or removal of 3 hepatic segments

          3. More than 1 lesion identified during baseline.

          4. Have previously received therapeutic treatment for HCC outside the study protocol or
             is expected to receive concomitant HCC treatment prior to PFS event.

          5. Have serious medical illnesses including, but not limited to, congestive heart
             failure, myocardial infarction or cerebral vascular accident within the last six
             months, or life threatening cardiac arrhythmias.

          6. Have previously received any anthracycline outside the protocol

          7. Have extrahepatic metastasis.

          8. Have portal or hepatic vein tumor invasion/thrombosis.

          9. Have body temperature &gt;101ºF (38.3ºC) immediately prior to study treatment.

         10. Baseline laboratories (repeat lab tests are permitted to evaluate eligibility during
             the Screening Period. Lab results must be within protocol range prior to study
             treatment.)

               -  Absolute neutrophil count &lt; 1500/mm3

               -  Platelet count &lt; 75,000/mm3

               -  Hgb &lt; 10.0 g/dL (unless the hemoglobin value has been stable, the subject is
                  cardiovascularly stable, asymptomatic and judged able to withstand the RFA
                  procedure) Note: If clinically indicated, subjects may receive platelets or
                  packed red blood cell (RBC) transfusions and be re-evaluated after condition is
                  treated.

         11. Baseline Chemistry

               -  Serum creatinine ≥ 2.5 mg/dL or calculated creatinine clearance (CrCl) ≤25.0
                  mL/min.

               -  Serum bilirubin &gt; 3.0 mg/dL.

               -  Serum albumin &lt; 2.8 g/dL.

         12. Have any known allergic reactions to any of the drugs or liposomal components or
             intravenous imaging agents that prohibit the ability to complete the imaging
             requirements.

         13. Are pregnant or breast-feeding. In women of childbearing potential, a negative serum
             pregnancy test is required prior to study treatment.

         14. Women of childbearing potential and men who are not practicing an acceptable form of
             birth control (i.e. diaphragm, cervical cap, condom, surgical sterility or birth
             control pills. Women whose partner has or men who have undergone a vasectomy must use
             a second form of birth control).

         15. Have INR &gt; 1.5 times the institution's upper normal limit (UNL), except in subjects
             who are therapeutically anticoagulated for medical conditions unrelated to HCC such as
             atrial fibrillation. Subjects may be re-screened after condition is treated or
             anticoagulant is withheld.

         16. Have contraindications to receiving doxorubicin hydrochloride (HCl).

         17. Are being treated with other investigational agents.

         18. Use of an investigational drug outside this study within 30 days or 5 half-lives,
             whichever is longer, preceding the first dose of study medication.

         19. Have other concurrent malignancy (subjects with treated squamous cell carcinoma of the
             skin or basal cell carcinoma of the skin may be included), evidence of extrahepatic
             cancer from their primary malignancy, or ongoing, medically significant active
             infection.

         20. HIV positive.

         21. NYHA class III or IV functional classification for heart failure.

         22. Evidence of hemachromatosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ricardo Lencioni, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Pisa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ronnie Tung Ping Poon, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hong Kong University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chen Min Hua, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicholas Borys, MD</last_name>
    <email>nborys@celsion.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Craig Pfister</last_name>
    <email>cpfister@celsion.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCLA Department of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Paroly</last_name>
      <phone>310-825-4493</phone>
      <email>jparoly@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Richard Finn, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lou Magdale</last_name>
      <phone>416-946-4501</phone>
      <phone_ext>6639</phone_ext>
    </contact>
    <investigator>
      <last_name>John Kachura, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mengchao Hepatobiliary Hospital of Fujian Medicatl University</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350005</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shunfeng Luo</last_name>
      <email>494782606@qq.com</email>
    </contact>
    <investigator>
      <last_name>Jingfeng Liu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Institution and Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yinghua Zou, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital, School of Oncology, Peking</name>
      <address>
        <city>Beijing</city>
        <zip>100036</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Min Hua Chen, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>302 Military Hospital of China</name>
      <address>
        <city>Beijing</city>
        <zip>100039</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Huaming Wang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Youan Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <zip>100069</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Beijing Hospital of the Ministry of Health</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Junmin Wei, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kai Jiang</last_name>
      <phone>86-135 0117 2908</phone>
      <email>jiangk301@126.com</email>
    </contact>
    <investigator>
      <last_name>Kai Jiang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jia ChenYang</last_name>
      <email>huaxigonna@sina.com</email>
    </contact>
    <investigator>
      <last_name>Bo Li, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Third Military Medical University</name>
      <address>
        <city>Chongqing</city>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <zip>116023</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Liming Wang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangdong General Hospital</name>
      <address>
        <city>Guangdong</city>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ligong Lu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital, Sun Yat-Sen University</name>
      <address>
        <city>GuangZhou</city>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Hunan</city>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hellen Li</last_name>
      <email>hli@accelovance.com</email>
    </contact>
    <investigator>
      <last_name>Ruocai Xu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Jilin</city>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong Haixia</last_name>
      <email>dong_haixia@wuxiapptec.com</email>
    </contact>
    <investigator>
      <last_name>Hengjun Zhao, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xijing Hospital</name>
      <address>
        <city>Shaanxi Province</city>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Guohong Han, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Zhenggang Ren, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Changhai Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>The Sixth People's Hospital of Shenyang</name>
      <address>
        <city>Shenyang</city>
        <zip>110006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Wei Wu, P.I.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The 3rd Hospital of Tianjing</name>
      <address>
        <city>Tianjin</city>
        <zip>300170</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yijun Wang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Zhejiang</name>
      <address>
        <city>ZheJiang</city>
        <zip>310013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yan Shen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Zhejiang</city>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hellen Li</last_name>
      <email>hli@accelovance.com</email>
    </contact>
    <investigator>
      <last_name>Yi'an Du, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn, Medizinische Klinik und Poliklinik I</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Institut für Diagnostische und Radiologische Therapie del Uniklinik Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Camilla Scherer</last_name>
      <phone>49 69 6301 87212</phone>
      <email>camilla.scherer@kgu.de</email>
    </contact>
    <investigator>
      <last_name>Thomas Vogl, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München - Großhadern, Medizinische Klinik und Poliklinik II</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar, II. Medizinische Klinik und Poliklinik (Gastroenterologie)</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jens Zimmermann</last_name>
      <phone>49 89 4140 6706</phone>
      <email>studiensekretariat.med2@lrz.tum.de</email>
    </contact>
    <investigator>
      <last_name>Ursula Ehmer, M.D., PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Regensburg, Institut für Röntgendiagnostik</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simone Frankl</last_name>
      <phone>49 941 944-7486</phone>
    </contact>
    <investigator>
      <last_name>Philipp Wiggermann, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum des Saarlandes, Klik fuer Allgemeine Chirurgie, Viszeral-, Gefaess und Kinderchirurgie</name>
      <address>
        <city>Saar</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Berit Kopp</last_name>
      <phone>49 6841 163 1009</phone>
      <email>berit.kopp@uniklinikum-saarland.de</email>
    </contact>
    <investigator>
      <last_name>Robert Eisele, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henry Tam</last_name>
      <phone>852-2255-6646</phone>
      <email>mrhenrytam@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Tan To Cheung, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Papa Giovanni XXIII, Gastroenterologia, epatologia e trapiantologia</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, UOC Gastroenterologia ed Epatologia</name>
      <address>
        <city>Milan</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>S.S.D. Chirurgia Epatobiliare e Trapianti Epatici Azienda Ospedaliera di Padova</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Cisanello Hospital, Division of Diagnostic Imaging and Intervention</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo De Simone</last_name>
      <phone>39050995421</phone>
      <email>p.desimone@ao_pisa.toscana.it</email>
    </contact>
    <investigator>
      <last_name>Laura Crocetti, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Radiological Sciences and Bioimaging Catholic University of Rome, &quot;A. Gemelli&quot; Hospital</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Iezzi</last_name>
      <phone>+39 3477264452</phone>
      <email>roberto.iezzi.md@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Lorenzo Bonomo, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hye Young Lee</last_name>
      <phone>82-51-240-7078</phone>
      <email>prettyoung97@daum.net</email>
    </contact>
    <investigator>
      <last_name>Jeong Heo, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>700-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mi Joo Lee</last_name>
      <phone>82-53-420-6138</phone>
      <email>haime83@naver.com</email>
    </contact>
    <investigator>
      <last_name>Won-Young Tak, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Medical Center</name>
      <address>
        <city>Daegu</city>
        <zip>702-210</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sun Hee Lee</last_name>
      <phone>82-53-200-2536</phone>
      <email>shlie370@naver.com</email>
    </contact>
    <investigator>
      <last_name>Soo Young Park, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inje University Ilsan Paik Hospital</name>
      <address>
        <city>Goyang-si</city>
        <zip>411-706</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <zip>400-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hee Kyoung Shin</last_name>
      <phone>+82-32-890-1117</phone>
      <email>shinhee8610@naver.com</email>
    </contact>
    <investigator>
      <last_name>Yong Sun Jeon, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soo Yeon Kang</last_name>
      <phone>+82 2-2072-3073</phone>
      <email>jumper6805@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jae-Young Lee, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mi Yeon Cho</last_name>
      <phone>82-2-2228-0811</phone>
      <email>jjomi0318@yuhs.ac</email>
    </contact>
    <investigator>
      <last_name>Do Young Kim, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jung-Eun Kim</last_name>
      <phone>82-2-3410-6962</phone>
      <email>ciel625@naver.com</email>
    </contact>
    <investigator>
      <last_name>Hyun Chul Rhim, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul St.Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sung Hee Kim</last_name>
      <phone>82-2-2258-7613</phone>
      <email>sakura3508@naver.com</email>
    </contact>
    <investigator>
      <last_name>Jong Young Choi, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Malaya Medical Centre</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sowdamany Kumaran Nair</last_name>
      <phone>60129414688</phone>
      <email>sowda.nair@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Basri Johan Jeet Abdullah, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nilai Medical Centre</name>
      <address>
        <city>Negeri Sembilan</city>
        <zip>71800</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Chinese General Hospital and Medical Center</name>
      <address>
        <city>Manila</city>
        <zip>1003</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Micah Nazareno</last_name>
      <phone>63 2 7114141</phone>
      <phone_ext>1704</phone_ext>
      <email>micah_naz18@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Stephen Wong, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Medical City</name>
      <address>
        <city>Metro Manila</city>
        <zip>1605</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>St. Lukes Medical Center</name>
      <address>
        <city>Quezon City</city>
        <zip>1112</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Doris Aceberos</last_name>
      <phone>632 723 0101</phone>
      <phone_ext>4178</phone_ext>
      <email>daceberos@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Julieta Gopez Cervantes, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardinal Santos Medical Center</name>
      <address>
        <city>San Juan</city>
        <zip>1503</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracy Vienne Ferrer</last_name>
      <phone>6327237474</phone>
      <email>tracyvienneacobferrer@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jose Sollano Jr., M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Singapore General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>• Nur Hazwanie Begum</last_name>
      <phone>65 93821090</phone>
      <email>nur.hazwanie.begum.abdul.latiff@sgh.com.sg</email>
    </contact>
    <investigator>
      <last_name>Richard Lo, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Santiago</name>
      <address>
        <city>La Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hospital Madrid Norte Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gemma Sanchez</last_name>
      <phone>34917567984</phone>
      <email>gsanchez@fundacionhm.com</email>
    </contact>
    <investigator>
      <last_name>Antonio Cubillo, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital, Yun-Lin Branch</name>
      <address>
        <city>Douliou City</city>
        <zip>640</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Huang</last_name>
      <phone>886 5 5323911</phone>
      <phone_ext>2200</phone_ext>
      <email>ch87415@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Shih-Jer Hsu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital - Kaohsiung</name>
      <address>
        <city>Kaohsiung</city>
        <zip>833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui Ling Hsu</last_name>
      <phone>886-7-7317123</phone>
      <phone_ext>3192</phone_ext>
      <email>diodio.diodio@msa.hinet.net</email>
    </contact>
    <investigator>
      <last_name>Jing-Houng Wang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taipei Medical University-Shuang Ho Hospital</name>
      <address>
        <city>New Taipei City</city>
        <zip>235</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Le Yan Lai</last_name>
      <phone>886-2-2249-0088</phone>
      <phone_ext>8171</phone_ext>
      <email>08359@s.tmu.edu.tw</email>
    </contact>
    <investigator>
      <last_name>Li-Wei Wu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>404</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Taichung Veteran General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>407</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie-Ling Yen</last_name>
      <phone>886 989 610 899</phone>
      <email>c9626@yahoo.com.tw</email>
    </contact>
    <investigator>
      <last_name>Teng-Yu Lee, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University (NCKU) Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ting-Ting Yang</last_name>
      <phone>892 6-2353535</phone>
      <phone_ext>3588</phone_ext>
      <email>ttyang3588@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Ting-Tsung Chang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei City</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui-Chen Lin</last_name>
      <phone>886-2-23123456</phone>
      <phone_ext>67266</phone_ext>
      <email>vivin2100@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ja-Der Liang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mackay Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10449</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital - Linkou</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie-Sin Chao</last_name>
      <phone>886-3-3281200</phone>
      <phone_ext>2223</phone_ext>
    </contact>
    <investigator>
      <last_name>Shi-Ming Lin, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chulalongkorn University Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Siriraj Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siriluck Leelawadee</last_name>
      <phone>662 419 7280-2</phone>
      <email>leelawadee_siri@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Tawesak Tanwandee, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maharaj Nakorn Chiang Mai Hospital</name>
      <address>
        <city>Chiang Mai</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thanate Kattipathanapong, M.D.</last_name>
      <email>thanate.k@cmu.ac.th</email>
    </contact>
    <investigator>
      <last_name>Busyamas Chewaskulyong, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Srinagarind Hospital</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monthian Boonto</last_name>
      <phone>6643-366558</phone>
    </contact>
    <investigator>
      <last_name>Wattana Sukeepaisarnjaroen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thammasat University Hospital</name>
      <address>
        <city>Pathumthani</city>
        <zip>12120</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juraiwan Namtanee</last_name>
      <phone>662-926-9793</phone>
      <email>namtanee99@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ratha-Korn Vilaichone, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Songklanagarind Hospital</name>
      <address>
        <city>Songkhla</city>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Supannarangsri Pongpanich</last_name>
      <phone>66-74-451965-9</phone>
    </contact>
    <contact_backup>
      <email>supannarangsrip@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Teerha Piratvisuth, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bach Mai Hospital</name>
      <address>
        <city>Hà Nội</city>
        <state>Dong Da District</state>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Le Lam Ngo, M.D.</last_name>
      <email>lamntxq28@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Thong Minh Pham, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>108 Military Central Hospital</name>
      <address>
        <city>Hà Nội</city>
        <state>Hai Ba Trung District</state>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tien Thinh Nguyen, M.D.</last_name>
      <email>nguyentienthinha3108@yahoo.com.vn</email>
    </contact>
    <investigator>
      <last_name>Bang Hong Mai, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hue Central Hospital</name>
      <address>
        <city>Huế</city>
        <state>Vin Ninh Ward</state>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thanh Xuan Nguyen, M.D.</last_name>
      <email>thanhxuan82vn@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Hiep Nhu Pham, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bach Mai Hospital (Hepato-gastroenterology Department)</name>
      <address>
        <city>Hanoi</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nguyen Thu Thuy</last_name>
      <phone>841659 037073</phone>
      <email>thuynguyenthu@viefstar-research.com</email>
    </contact>
    <investigator>
      <last_name>Truong Khanh Vu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Can Tho Oncology Hospital</name>
      <address>
        <city>Hanoi</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Long Hien Ho, M.D.</last_name>
      <email>hienholong@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Long Hien Ho, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Hospital</name>
      <address>
        <city>Hanoi</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Van Giang Bui, M.D.</last_name>
      <email>buivangiang@hmu.edu.vn</email>
    </contact>
    <investigator>
      <last_name>Van Giang Bui, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Viet Duc University Hospital</name>
      <address>
        <city>Hanoi</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong Son Trinh</last_name>
      <phone>84913056779</phone>
      <email>thsonvd@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Hong Son Trinh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>People's Hospital 115</name>
      <address>
        <city>Ho Chi Minh City</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thi Ai Phuong Truong, M.D.</last_name>
      <email>truongthiaiphuong@yahoo.com.vn</email>
    </contact>
    <investigator>
      <last_name>Phuong Thi Tuyet Le, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>China</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Philippines</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United States</country>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2014</study_first_submitted>
  <study_first_submitted_qc>April 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2014</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Carcinoma</keyword>
  <keyword>Carcinoma, Hepatocellular</keyword>
  <keyword>Neoplasms, Glandular and Epithelial</keyword>
  <keyword>Neoplasms by Histologic Type</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Adenocarcinoma</keyword>
  <keyword>Liver Neoplasms</keyword>
  <keyword>Digestive System Neoplasms</keyword>
  <keyword>Neoplasms by Site</keyword>
  <keyword>Digestive System Diseases</keyword>
  <keyword>Liver Diseases</keyword>
  <keyword>Doxorubicin</keyword>
  <keyword>Antibiotics, Antineoplastic</keyword>
  <keyword>Antineoplastic Agents</keyword>
  <keyword>Therapeutic Uses</keyword>
  <keyword>Pharmacologic Actions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Antineoplastic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

